Literature DB >> 23715160

Postoperative nodal status and diffuse-type histology are independent prognostic factors in resectable advanced gastric carcinomas after preoperative chemotherapy.

Young Wha Koh1, Young Soo Park, Min-Hee Ryu, Baek-Yeol Ryoo, Hye Jin Park, Jeong Hwan Yook, Byung Sik Kim, Yoon-Koo Kang.   

Abstract

Surgical resection of primary gastric lesions after neoadjuvant or palliative chemotherapy is performed for curative or palliative purpose in locally advanced (LA) or initially metastatic (IM) gastric cancer. We investigated which histomorphologic features were associated with patient prognosis. We examined 143 patients (57 LA and 86 IM) who underwent gastrectomy after chemotherapy between 2000 and 2009. The tumor regression grade (TRG)-determined by examining the residual neoplastic cells and background stromal changes-was evaluated. Progression-free (PFS) and overall survival (OS) were evaluated according to pretherapeutic and posttherapeutic clinicopathologic factors using univariate and multivariate analyses. Because both the LA and the IM groups showed similar trends of PFS and OS according to TRG, the 2 groups were analyzed together. Patients with TRG1 (no residual primary tumor) showed a superior PFS and OS than the remaining TRGs. We defined pathologic complete regression (pCR) as TRG1 with negative lymph nodes (LN) and the others as non-pCR. Sixteen patients (11.1%) had pCR with better PFS (P=0.007) and OS (P=0.006). Initial disease status (LA or IM) remained as independent prognostic factors for PFS (P=0.021) but not for OS (P=0.109). The postoperative negative LN status correlated with good outcome and postoperative diffuse-type histology correlated with poor outcome after multivariate analysis. This study showed that pCR, but not partial regression, provides meaningful prognostic information in gastrectomy after chemotherapy. In addition, postoperative LN positivity and diffuse-type histology were independent poor prognostic factors for PFS and OS.

Entities:  

Mesh:

Year:  2013        PMID: 23715160     DOI: 10.1097/PAS.0b013e31828778fd

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  11 in total

1.  Conversion surgery after combination chemotherapy of docetaxel, cisplatin and S-1 (DCS) for far-advanced gastric cancer.

Authors:  Hiroaki Mieno; Keishi Yamashita; Kei Hosoda; Hiromitsu Moriya; Katsuhiko Higuchi; Mizutomo Azuma; Shouko Komori; Tsutomu Yoshida; Satoshi Tanabe; Wasaburo Koizumi; Natsuya Katada; Masahiko Watanabe
Journal:  Surg Today       Date:  2017-04-01       Impact factor: 2.549

2.  Gastric carcinoma: stage migration by immunohistochemically detected lymph node micrometastases.

Authors:  Theresa L A Jeuck; Christian Wittekind
Journal:  Gastric Cancer       Date:  2014-02-19       Impact factor: 7.370

3.  Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis.

Authors:  Fausto Petrelli; Rosa Berenato; Luca Turati; Alessia Mennitto; Francesca Steccanella; Marta Caporale; Pierpaolo Dallera; Filippo de Braud; Ezio Pezzica; Maria Di Bartolomeo; Giovanni Sgroi; Vincenzo Mazzaferro; Filippo Pietrantonio; Sandro Barni
Journal:  J Gastrointest Oncol       Date:  2017-02

4.  ypTNM staging after neoadjuvant chemotherapy in the Chinese gastric cancer population: an evaluation on the prognostic value of the AJCC eighth edition cancer staging system.

Authors:  Ziyu Li; Yinkui Wang; Fei Shan; Xiangji Ying; Zhouqiao Wu; Kan Xue; Rulin Miao; Yan Zhang; Jiafu Ji
Journal:  Gastric Cancer       Date:  2018-05-10       Impact factor: 7.370

5.  Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas.

Authors:  T Schmidt; L Sicic; S Blank; K Becker; W Weichert; T Bruckner; T Parakonthun; R Langer; M W Büchler; J-R Siewert; F Lordick; K Ott
Journal:  Br J Cancer       Date:  2014-02-25       Impact factor: 7.640

6.  Prognostic factors associated with locally advanced gastric cancer patients treated with neoadjuvant chemotherapy followed by surgical resection.

Authors:  Yongkun Sun; Lin Yang; Chengfeng Wang; Dongbing Zhao; Jianqiang Cai; Wenbin Li; Wen Zhang; Jing Huang; Aiping Zhou
Journal:  Oncotarget       Date:  2017-09-06

7.  Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis.

Authors:  Jwa Hoon Kim; Sook Ryun Park; Min-Hee Ryu; Baek-Yeol Ryoo; Kyu-Pyo Kim; Beom Su Kim; Moon-Won Yoo; Jeong Hwan Yook; Byung Sik Kim; Jihun Kim; Sun-Ju Byeon; Yoon-Koo Kang
Journal:  Cancer Res Treat       Date:  2017-05-24       Impact factor: 4.679

8.  Long-term Results of Conversion Therapy for Initially Unresectable Gastric Cancer: Analysis of 122 Patients at the National Cancer Center in China.

Authors:  Tongbo Wang; Nianchang Wang; Hu Ren; Hong Zhou; Aiping Zhou; Jing Jin; Yingtai Chen; Dongbing Zhao
Journal:  J Cancer       Date:  2019-10-15       Impact factor: 4.207

9.  Short-Term Clinical Efficacy of Neoadjuvant Chemotherapy Combined With Laparoscopic Gastrectomy for Locally Advanced Siewert Type II and III Adenocarcinoma of the Esophagogastric Junction: A Retrospective, Propensity Score-Matched Study.

Authors:  Qing Feng; Du Long; Ming-Shan Du; Xiao-Song Wang; Zhen-Shun Li; Yong-Liang Zhao; Feng Qian; Yan Wen; Pei-Wu Yu; Yan Shi
Journal:  Front Oncol       Date:  2021-09-29       Impact factor: 6.244

10.  Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis.

Authors:  Ziyu Li; Fei Shan; Yinkui Wang; Yan Zhang; Lianhai Zhang; Shuangxi Li; Yongning Jia; Kan Xue; Rulin Miao; Zhemin Li; Jiafu Ji
Journal:  PLoS One       Date:  2018-01-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.